文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

成人暴发性紫癜的临床谱与短期结局:法国多中心回顾性队列研究

Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study.
PubMed 文献 · Intensive Care Med · 2018-08-20
一句话结论成人感染性暴发性紫癜需血管升压药支持者院内死亡率41.2%,肺炎链球菌感染与截肢风险独立相关(亚风险比1.89)。

该研究为法国55个ICU、2000至2016年的17年全国多中心回顾性队列,纳入306例需血管升压药支持的成人感染性暴发性紫癜患者。随访期[13(3-24)天]内126例(41.2%,95%CI 35.6-46.9)死亡,180例存活者中51例(28.3%,95%CI 21.9-35.5)最终需截肢,中位截肢肢体数为3(1-4)个。主要病原体为脑膜炎奈瑟菌(63.7%)和肺炎链球菌(21.9%)。多变量Cox模型显示SAPS II、较低白细胞计数、较低血小板计数和动脉血乳酸水平与院内死亡独立相关,颈强直为保护因素;竞争风险分析显示肺炎链球菌感染与截肢独立相关(亚风险比1.89,95%CI 1.06-3.38,p=0.032)。

要点

  • 306例需血管升压药支持的成人感染性暴发性紫癜患者中,126例(41.2%,95%CI 35.6-46.9)死亡,180例存活者中51例(28.3%,95%CI 21.9-35.5)需截肢。
  • 截肢者中位截肢肢体数为3(1-4)个,随访期[13(3-24)天]内死亡与截肢负荷均高。
  • 多变量Cox模型:SAPS II每升高1分院内死亡HR 1.03(1.02-1.04,p<0.001),动脉血乳酸HR 2.71(1.68-4.38,p<0.001)。
  • 较低白细胞计数[HR 0.83(0.69-0.99),p=0.034]和较低血小板计数[HR 0.77(0.60-0.91),p=0.007]与院内死亡独立相关,颈强直为保护因素[HR 0.51(0.28-0.92),p=0.026]。
  • 竞争风险分析:肺炎链球菌感染与截肢独立相关[亚风险比1.89(1.06-3.38),p=0.032],作者结论认为肺炎链球菌暴发性紫癜截肢风险更高。

适用人群与场景

  • 法国55个ICU、2000至2016年收治的成人感染性暴发性紫癜患者,定义需满足突发广泛紫癜且需血管升压药支持。

诊断标准与关键阈值

  • 感染性暴发性紫癜定义:突发且广泛的紫癜,同时需要血管升压药支持。

研究设计与关键结果

  • 研究类型:17年全国多中心回顾性队列研究,55个ICU,纳入306例成人感染性暴发性紫癜患者。
  • 主要结局:随访期[13(3-24)天]内126例(41.2%,95%CI 35.6-46.9)死亡,180例(58.8%,95%CI 53.3-64.3)存活。
  • 存活者中51/180例(28.3%,95%CI 21.9-35.5)最终需截肢,中位截肢肢体数3(1-4)个。
  • 病原体:脑膜炎奈瑟菌63.7%,肺炎链球菌21.9%。
  • 多变量Cox模型与院内死亡独立相关:SAPS II [HR 1.03(1.02-1.04),p<0.001]、较低白细胞计数[HR 0.83(0.69-0.99),p=0.034]、较低血小板计数[HR 0.77(0.60-0.91),p=0.007]、动脉血乳酸[HR 2.71(1.68-4.38),p<0.001];颈强直为保护因素[HR 0.51(0.28-0.92),p=0.026]。
  • 竞争风险分析:肺炎链球菌感染[亚风险比1.89(1.06-3.38),p=0.032]连同动脉血乳酸水平和ICU入住时体温与截肢独立相关。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为暴发性紫癜死亡率和致残率高,肺炎链球菌暴发性紫癜导致更高的截肢风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Data on purpura fulminans (PF) in adult patients are scarce and mainly limited to meningococcal infections. Our aim has been to report the clinical features and outcomes of adult patients admitted in the intensive care unit (ICU) for an infectious PF, as well as the predictive factors for limb amputation and mortality.

METHODS: A 17-year national multicenter retrospective cohort study in 55 ICUs in France from 2000 to 2016, including adult patients admitted for an infectious PF defined by a sudden and extensive purpura, together with the need for vasopressor support. Primary outcome variables included hospital mortality and amputation during the follow-up period (time between ICU admission and amputation, death or end of follow-up).

RESULTS: Among the 306 included patients, 126 (41.2%; 95% CI 35.6-46.9) died and 180 (58.8%; 95% CI 53.3-64.3) survived during the follow-up period [13 (3-24) days], including 51/180 patients (28.3%, 95% CI 21.9-35.5) who eventually required limb amputations, with a median number of 3 (1-4) limbs amputated. The two predominantly identified microorganisms were Neisseria meningitidis (63.7%) and Streptococcus pneumoniae (21.9%). By multivariable Cox model, SAPS II [hazard-ratio (HR) = 1.03 (1.02-1.04); p < 0.001], lower leucocytes [HR 0.83 (0.69-0.99); p = 0.034] and platelet counts [HR 0.77 (0.60-0.91); p = 0.007], and arterial blood lactate levels [HR 2.71 (1.68-4.38); p < 0.001] were independently associated with hospital death, while a neck stiffness [HR 0.51 (0.28-0.92); p = 0.026] was a protective factor. Infection with Streptococcus pneumoniae [sub-hazard ratio 1.89 (1.06-3.38); p = 0.032], together with arterial lactate levels and ICU admission temperature, was independently associated with amputation by a competing risks analysis.

CONCLUSION: Purpura fulminans carries a high mortality and morbidity. Pneumococcal PF leads to a higher risk of amputation.

TRIALS REGISTRATION: NCT03216577.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Contou D, Sonneville R, Canoui-Poitrine F, et al. Clinical spectrum and short-term outcome of adult patients with purpura fulminans: a French multicenter retrospective cohort study. Intensive Care Med. 2018. PMID: 30128591. doi:10.1007/s00134-018-5341-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。